Harnessing the power of scientific innovation to create truly novel products for the market benefit of patients worldwide
Our unique model leverages a preferred position to source technology including first access and rights to disruptive deal flow. With visibility and access to Mass General Brigham's vast intellectual property estate, we have a privileged positioned to originate new ventures to advance novel medicines.
We are experienced innovators, entrepreneurs, executives, and investors. We work side-by-side with our scientific founders to build companies around innovative science.
We found and invest in new ventures based on novel life science technologies emerging from Mass General Brigham’s world-class research community.
Leading a translation powerhouse
Our Venture Capital team leads Mass General Brigham’s Translation powerhouse with $380 million in capital across three funds, investing in and accelerating breakthrough technologies based on our exclusive access to our network of hospitals.
Our translation platform includes multiple commercialization programs for advancing projects to the seed stage where they will attract venture capital investment. These funding sources serve as a powerful substrate to increase the probability of success (PoS) in some of the most promising areas of medical research. We combine these collective resources with our venture funding and company-building capabilities to enable transformative technologies that are primed for clinical application.
Mass General Brigham Innovation has invested more in translational research than any other program in the United States, with exceptional commercial and financial outcomes. Learn more about our Powerhouse to accelerate translation at all levels of research.
Investing in bold,
Research is the driving force that advances medicine and we sit at the center of the largest medical research engine in the United States. Mass General Brigham’s academic hospitals and Harvard Medical School faculty serve as a primary source of intellectual capital assets for venture investments with $2 billion in federal funding annually, and over 6,000 investigators. Our teams of investigators bring forth new and effective ways to diagnose, prevent, and cure disease every day. We work side-by-side with our scientific founders to build companies around innovative science and to provide the early-stage care and feeding necessary to thrive.